Groupe d'Etude en Oncologie du Quebec

Titre	A Phase 3 Randomized Study Comparing Nivolumab and Ipilimumab Combination vs Placebo in Participants With Localized Renal Cell Carcinoma Who Underwent Radical or Partial Nephrectomy and Who Are at High Risk of Relapse
Protocole ID	CA209-914
ClinicalTrials.gov ID	NCT03138512
Type(s) de cancer	Rein
Phase	Phase III
Stade	Adjuvant
Type étude	Traitement
Médicament	nivolumab et ipilimumab
Institution	CISSS DU BAS-SAINT-LAURENT HOPITAL REGIONAL DE RIMOUSKI 150 av. Rouleau, Rimouski, QC, G5L 5T1
Ville	Rimouski
Investigateur(trice) principal(e)	Dre Gabrielle Gagnon
Coordonnateur(trice)	Isabelle Gagnon 418-724-3000 poste 8029
Statut	Actif en recrutement
Critètes d'éligibilité	Kidney tumor has been completely resected 4 to 12 weeks prior to randomization Pathologic TNM staging meeting one of the following: pT2a, G3 or G4, N0 M0; pT2b, G any, N0 M0; pT3, G any, N0 M0; pT4, G any, N0 M0; pT any, G any, N1 M0 Post-nephrectomy tumor shows RCC with a predominantly clear cell histology, including participants with sarcomatoid features
Critètes d'exclusion	Participants with an active known or suspected autoimmune disease Known history of positive test for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS) Any severe or serious, acute or chronic medical or psychiatric condition, or laboratory abnormality that may increase the risk associated with study participation Participants with a condition requiring systemic treatment with corticosteroids

Groupe d'étude en oncologie du Québec